IP Library Granted Patent US 8,013,002
Granted Patent B2
US 8,013,002 · App. 13/049,894 · Granted Sep 6, 2011

Methods of administering pirfenidone therapy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,013,002
App. No.
13/049,894
Granted
Sep 6, 2011
Kind
B2
Abstract

The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.

Claims (11)

1. A method of administering pirfenidone and fluvoxamine concurrently to a patient in need thereof comprising administering a therapeutically effective amount of fluvoxamine to the patient and administering a therapeutically effective amount of pirfenidone to the patient, wherein the amount of the pirfenidone is about 801 mg/day.

2. The method of claim 1 wherein the pirfenidone is administered three times per day.

3. The method of claim 2 wherein the patient has idiopathic pulmonary fibrosis (IPF).

4. The method of claim 3 wherein the pirfenidone is administered to the patient with food.

5. The method of claim 1 further comprising discontinuing co-administration of fluvoxamine and administering a therapeutically effective amount of pirfenidone.

6. A method of providing pirfenidone therapy to a patient in need thereof comprising titrating the dosage of pirfenidone administered to the patient downward from a dose of about 2400 mg/day, while co-administering fluvoxamine, wherein the dose of pirfenidone is reduced by about 1600 mg/day.

7. The method of claim 6 wherein about 800 mg/day of pirfenidone is administered to the patient.

8. The method of claim 6 wherein the pirfenidone is administered three times per day.

9. The method of claim 8 wherein the patient has idiopathic pulmonary fibrosis (IPF).

10. The method of claim 9 wherein the pirfenidone is administered to the patient with food.

11. The method of claim 6 further comprising discontinuing co-administration of fluvoxamine and administering about 2400 mg/day of pirfenidone.

Assignments (4)
SECURITY INTEREST Recorded Mar 23, 2026
From: LEGACY PHARMA INC. SEZC
To: ROOSTER LP
Reel/Frame 074151/0761 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2025
From: INTERMUNE, INC.
To: LEGACY PHARMA INC. SEZC
Reel/Frame 070877/0547 →
CERTIFICATE OF CHANGE OF COMPANY'S ADDRESS Recorded Jul 27, 2018
From: INTERMUNE, INC.
To: INTERMUNE, INC.
Reel/Frame 046638/0466 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2011
From: BRADFORD, WILLIAMSON Z.; SZWARCBERG, JAVIER
To: INTERMUNE, INC.
Reel/Frame 026021/0238 →